2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2436

Views and Prescribing Habits of Pneumocystis Prophylaxis in the Pediatric Rheumatology Community
Abstract Number: 3150

Virtual Peer-to-Peer Mentoring Support for Adolescents with Juvenile Idiopathic Arthritis: The Virtual Peer-to-Peer Program
Abstract Number: 1823

Visceral Adiposity in Premenopausal Lupus Patients: Correlation with Systemic Inflammation
Abstract Number: 2648

Vitality, Presenteeism, and Their Determinants in Patients with Early Rheumatoid Arthritis Treated with a 6-Month Induction Infliximab Therapy Added on a Triple Combination Therapy
Abstract Number: 3174

Vitamin D Binding Protein and Tenofovir-Associated Bone Loss Among Individuals with HIV
Abstract Number: 675

Vitamin D Deficiency in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis. Results of the CARMA Study
Abstract Number: 2231

Vitamin D Deficiency States Can be Actively Prevented. Results from a Cross-Sectional Study of over 3000 Patients with Rheumatic Diseases
Abstract Number: 2678

Vitamin D Serum Level in Early Arthritis Patients: Association with Disease Activity, Disability and Severity in the Espoir Cohort
Abstract Number: 2958

Vitamin D, Cognition and Cerebral Structural Abnormalities in Childhood- Onset Systemic Lupus Erythematosus
Abstract Number: 240

Volumetric Assessment of Tophaceous Gout
Abstract Number: 1586

Weight Loss in Obese Rheumatoid Arthritis (RA) Patients Improves Disease Activity without Modifying RA Treatment
Abstract Number: 2117

Weight Predicts Back Pain in Young Adult Women, Independent of Physical Activity: Data from the Australian Longitudinal Study on Women’s Health
Abstract Number: 234

Weight Variables and Their Association with Serum Urate Concentrations and Hyperuricemia in Young Adults
Abstract Number: 255

What Acute Phase Reactants Accurately Identify Patients Who Will Develop Amyloidosis in Familial Mediterranean Fever? a Systematic Review
Abstract Number: 2775

What Factors Are Associated with Starting an Intravenous Vs. Sub-Cutaneous Biologic in Patients with RA?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].